SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.

ABSTRACT: The coronavirus disease 2019 (COVID-19) pandemic presents an urgent health crisis. Human neutralizing antibodies that target the host ACE2 receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein^1-5 show promise therapeutically and are being evaluated clinically^6-8. Here, to identify the structural correlates of SARS-CoV-2 neutralization, we solved eight new structures of distinct COVID-19 human neutralizing antibodies⁵ in complex with the SARS-CoV-2 spike trimer or RBD. Structural comparisons allowed us to classify the antibodies into categories: (1) neutralizing antibodies encoded by the VH3-53 gene segment with short CDRH3 loops that block ACE2 and bind only to 'up' RBDs; (2) ACE2-blocking neutralizi

SUBMITTER: Barnes CO 

PROVIDER: S-EPMC8092461 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature